Strategic transformation

November 2023

Hornby plc: Strategic Transformation (B)

By Freek Vermeulen

In 2005 Frank Martin, CEO of Hornby, was feeling proud. Since joining in 2000, he had seen the company's share price rise from 35 to more than 250 and his strategic transformation of the firm from a toy company into a hobby company had been a resounding success. The company dominated the UK market a...

November 2023

Hornby plc: Building Communities (A)

By Freek Vermeulen

In 2005 Frank Martin, CEO of Hornby, was feeling proud. Since joining in 2000, he had seen the company's share price rise from 35 to more than 250 and his strategic transformation of the firm from a toy company into a hobby company had been a resounding success. The company dominated the UK market a...

October 2022

The Strategic Transformation of Royal Philips

By Freek Vermeulen, Ronald de Jong

In April 2011, Dutch multinational Royal Philips, one of the most iconic companies in the country, decided to disrupt itself and transform from a diversified industrial conglomerate to a focused player in Health Technology. The case describes the first decade (2011-2021) of the strategic transformat...

April 2024

Building an organisation for the ecosystem era: Weighing up the Recipe of Haier’s Internet of Food

By Michael Jacobides, Tom Albrighton, Monwei Chou, Lisa Duke, Dalbert Ma, Aryan Mittal

Ecosystems offer a new way to bring multiple firms together in order to deliver new value propositions. By working together, the hub firm and its complementors can create innovative ‘product plus service’ bundles that span traditionally separate industries to offer an experience that simply wasn...

April 2024

From Products to Experience Ecosystems: Haier’s Internet of Food

By Michael Jacobides, Lisa Duke, Dalbert Ma, Aryan Mittal

Haier had come a long way since Zhang Ruimin took it over as a failing Chinese Collective-Owned Enterprise in 1984. Since then, he’d been able to transform it into one of the world’s leading appliance manufacturers, known for quality and innovation. Haier was also noted for its bold geographical...

March 2022

Refinitiv: A private equity-led transformation

By Julian Birkinshaw, David Craig

In August 2019 CEO David Craig was considering the likely benefits and challenges of merging his company, financial-markets data and infrastructure provider Refinitiv, with the London Stock Exchange Group. Craig had led a turnaround of Thomson Reuters’ Financial & Risk division (F&R), then...

October 2020

Takeda: The governance of strategic transformation (B) (Japanese language)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to three therapeutic areas, reorganised its global R&D fo...

October 2020

Takeda: The Governance of Strategic Transformation (A) (Japanese language)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to three therapeutic areas, reorganised its global R&D fo...

November 2018

Takeda: The governance of strategic transformation (B)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to three therapeutic areas, reorganised its global R&D fo...

November 2018

Takeda: The governance of strategic transformation (A)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to three therapeutic areas, reorganised its global R&D fo...